Late­com­er Am­gen takes 'plat­form ap­proach' in obe­si­ty as PhII da­ta loom

As Am­gen catch­es up with lead­ers in the bur­geon­ing obe­si­ty space, it’s un­der­scor­ing a “plat­form ap­proach” and shoot­ing for “broad op­tion­al­i­ty” in the de­sign of its Phase III.

Speak­ing at the Bank of Amer­i­ca Mer­rill Lynch Glob­al Health­care Con­fer­ence, Am­gen CFO Pe­ter Grif­fith spot­light­ed two of its obe­si­ty pro­grams: AMG 133, a Phase II pro­gram that’s been named maride­bart cafraglu­tide, or mari; and the Phase I can­di­date AMG 786. Mari is “en­rolling well,” he not­ed; the study is ten­ta­tive­ly set to read out in late 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER